12 September 2016
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Change of Adviser
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, is pleased to announce the appointment of finnCap Ltd as Nominated Adviser and Broker to the Company with immediate effect.
Notes to Editors
For further information from Avacta Group plc, please contact:
Avacta Group plc
Alastair Smith, Chief Executive Officer
Tony Gardiner, Chief Financial Officer
Tel: +44 (0) 844 414 0452
Geoff Nash / Giles Rolls - Nominated Adviser
Tim Redfern / Alice Lane - Corporate Broking
Tel: +44 (0) 207 220 0500
Tel: +44 (0) 203 705 9318
Tel: +44 (0) 203 705 9217
FTI Consulting (Financial Media and IR)
Simon Conway / Natalie Garland-Collins
Tel: +44 (0) 203 727 1000
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $75bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of targets to enable diagnostics, research assays and therapeutics.
Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
This information is provided by RNS